Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.
D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors; D000808:Angiotensinogen / Q000097:blood; D001341:Autonomic Nervous System / Q000187:drug effects*; D001794:Blood Pressure / Q000187:drug effects; D002319:Cardiovascular System / Q000187:drug effects*; D002395:Catecholamines / Q000097:blood; D004151:Dipeptides / Q000494:pharmacology*; D004656:Enalapril; D004702:Endocrine Glands / Q000187:drug effects*; D006801:Humans; D017706:Lisinopril; D008297:Male; D008875:Middle Aged; D012083:Renin / Q000097:blood
D000806:Angiotensin-Converting Enzyme Inhibitors; D002395:Catecholamines; D004151:Dipeptides; D000808:Angiotensinogen; D004656:Enalapril; D017706:Lisinopril; D012083:Renin